The is now in place, effective June 4, 2024. The policy was developed to define the responsibilities of the University鈥檚 , as it pertains to the management of prospective therapeutic interventional research that is conducted or supported by employees of the University. Among other IDS-specific procedures, the policy specifies that:
- All human subject research involving drugs as the test object of a study will undergo ancillary review by IDS; and
- Study teams are expected to delegate drug management responsibilities to IDS.
Study teams wishing to use methods other than IDS to manage investigational drugs will need to submit an or review.
The policy and exemption request process will be reviewed during the 聽(with the recording available for later viewing via OHSP鈥檚 UR-HRPP Educational Materials).
For questions regarding UR-HRPP Educational Forums, contact Kelly Unsworth.